CXCR2 and breast carcinoma: These results showed that the CXCR2 antagonist obviously enhanced the therapeutic efficacy of DTX and might be a promising candidate to increase anticancer efficacy of DTX in breast cancer, especially in CCL20high-expressing breast cancer, suggesting the combinational treatment may be more effective in CCL20high-expressing breast cancer patients.